Here is the synopsis of our sample research paper on Asthma Medication/Xolair. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
A 5 page research paper that reports on a new asthma drug called Xolair. This examination of this new drug describes its pharmacological properties, its cost and also its significance to nursing. Bibliography lists 5 sources.
Page Count:
5 pages (~225 words per page)
File: D0_khxolair.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
p. 243). Experts have approximated that 16 to 26 million adults have received a diagnosis of asthma at some point during their lives, and it is an escalating problem among
children (McKay, 2003). Between 1980 and 1995, there was a significant increase in asthma associated morbidity and mortality. While mortality rates reached a peak in 1995 and the rates
of hospitalization due to asthma attacks have decreased, visits to primary care physicians and emergency departments continue to rise according to the Centers for Disease Control and Prevention (CDC).
As this indicates, asthma is a vital concern of nursing. However, there is a new pharmacological weapon in the healthcare arsenal of effective interventions that can be used against this
debilitating illness - Xolair. The following examination of this new drug describes its pharmacological properties, its cost and also its significance to nursing. Pharmacological action and pertinent pharmacokinetics
Omalizumab, which is known by the brand name of Xolair, is the first "bio-tech" drug approved for the treatment of asthma. A recombinant humanized monoclonal antibody (rhuMAB-E25), it is intended
for the treatment of severe asthma in individual 12 years and older (Davydov, 2005). When immunoglobulin E (IgE) binds to its cognate receptors, it triggers a series of cellular
events (Owen, 2007). This action includes "presentation of antigen by dendritic cells" as well as the "degranulation of mast cells and basophils to release numerous factors," which all have a
perform a role in creating asthmatic symptoms (Owen, 2007., p. 121). The pharmacological action of Xolair involves binding IgE to its receptor, which is located on mast cells and basophils
(Davydov, 2005). Xolair is the first medication to stop asthma before it starts due to the way in which it blocks the
...